Resultados de la búsqueda 191-200 of 10692 for ✅
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...
The purpose of this study is to assess the presence of various molecular markers in histiocytic disorders. In addition to this, to review clinical records of ...
Rochester, Minn. Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these ...
This randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with ...
To describe the clinical, laboratory, pathologic, imaging findings, therapy and outcomes in all patients with Fibromuscular Dysplasia (FMD) and/or segmental ...
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
Jacksonville, Fla. The purpose of this study is to explore the translational abilities of desorption electrospray ionization mass spectrometry (DESI-MS) as ...
De Mayo Clinic a tu buzón. Inscríbete gratis y mantente al día en cuanto a avances en las investigaciones, consejos sobre salud, temas médicos de actualidad ...
The purpose of this study is to evaluate different techniques to repair internal iliac artery aneurysms. Report short and long term clinical outcomes with ...
Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?